1
|
Marcq G, Kool R, Dragomir A, Kulkarni G, Breau R, Kim M, Busca I, Abdi H, Dawidek M, Uy M, Fervaha G, Cury F, Alimohamed N, Izawa J, Jeldres C, Rendon R, Shayegan B, Siemens R, Black P, Kassouf W. Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment weighted analysis. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01335-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Thériault R, Ismail S, Bouchard F, Tétreault-Laflamme A, Richard P, Jeldres C, Morin C, Vallières É, Tu L. Retrospective study of mid- and long-term urinary complications in patients with prostate cancer treated with radiotherapy and/or radical prostatectomy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00303-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Beard C, Jeldres C, Odem-Davis K, Hoffman K, Martin N, Nguyen P, Porter C, Sweeney C, Kollmannsberger C, Nichols C. Variation in Patterns of Care in the United States for Clinical Stage I Seminoma: Results From the National Cancer Data Base (1998-2011). Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Sun M, Abdollah F, Shariat S, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz P. Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. Eur J Surg Oncol 2012; 38:80-7. [DOI: 10.1016/j.ejso.2011.09.035] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2011] [Revised: 08/12/2011] [Accepted: 09/15/2011] [Indexed: 01/31/2023] Open
|
5
|
Fajkovic H, Chromecki T, Cha E, Jeldres C, Breinl E, Donner G, Seitz C, Shariat S. Prognostic value of extranodal extension (ENE) and other lymph node parameters in patients with upper tract urothelial carcinoma. Journal of Men's Health 2011. [DOI: 10.1016/j.jomh.2011.08.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
6
|
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2011; 23:973-80. [PMID: 21890909 DOI: 10.1093/annonc/mdr362] [Citation(s) in RCA: 429] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND We assessed the distribution of site-specific metastases in patients with renal cell carcinoma (RCC) according to age. Moreover, we evaluated recommendations proposed by guidelines and focused specifically on bone and brain metastases. PATIENTS AND METHODS Patients with metastatic RCC (mRCC) were abstracted from the Nationwide Inpatient Sample (1998-2007). Age was stratified into four groups: <55, 55-64, 65-74 and ≥ 75 years. Cochran-Armitage trend test and multivariable logistic regression analysis tested the relationship between age and the rate of multiple metastatic sites. Finally, we examined the rates of brain or bone metastases according to the presence of other metastatic sites. RESULTS In 11,157 mRCC patients, the rate of multiple metastatic sites decreased with increasing age (P < 0.001). This phenomenon was confirmed in patients with lung, bone, liver and brain metastases (all P ≤ 0.01). The rate of bone metastases was 10% in patients with exclusive abdominal metastases and 49% in patients with abdominal, thoracic and brain metastases. The rate of brain metastases was 2% in patients with exclusive abdominal metastases and 16% in patients with thoracic and bone metastases. CONCLUSIONS The proportion of patients with multiple metastatic sites is higher in young patients. The rates of bone (10%-49%) and brain (2%-16%) metastases are nonnegligible in mRCC patients.
Collapse
Affiliation(s)
- M Bianchi
- Department of Urology, Vita-Salute University, Urological Research Institute, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Budäus L, Morgan M, Abdollah F, Zorn KC, Sun M, Johal R, Thuret R, Abdo A, Schmitges J, Isbarn H, Jeldres C, Perrotte P, Graefen M, Karakiewicz PI. Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: a population-based study. Eur J Surg Oncol 2011; 37:429-34. [PMID: 21492776 DOI: 10.1016/j.ejso.2011.02.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2010] [Revised: 01/29/2011] [Accepted: 02/28/2011] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND On average, patients remain hospitalized no more than 2 days after MIRP. The aim of our study was to examine the temporal trends in length of stay ≥ 3 days and to test the relationship between annual surgical volume (ASV) and annual hospital volume (AHV) and length of stay ≥ 3 days in patients undergoing MIRP. MATERIAL AND METHODS Within the Florida Hospital Inpatient Datafile, 2439 men who were treated with MIRP for prostate cancer between 2005 and 2008 were identified. Temporal trends were assessed and uni and multi-variable logistic regression models tested the relationship between ASV, AHV and length of stay ≥ 3 days. RESULTS The average length of stay decreased from 2.4 in 2005 to 1.7 days in 2008. Length of stay ≥ 3 days was recorded in 13.6% of patients and the proportion of patients staying more than ≥ 3 days decreased over time (25.5-12.2%; Chi Square trend p < 0.001). After stratification into low (<1-15 MIRPs) vs. intermediate (16-63 MIRPs) vs. high ASV tertiles (≥ 64 MIRPs) the proportion of patients with length of stay ≥ 3 days were 29.1; 13.2 and 11.1%. In multivariable logistic regression models predicting length of stay ≥ 3 days, ASV, year of surgery and comorbidities achieved independent predictor status and MIRP patients operated by highest ASV tertile surgeons were 71% (p < 0.001) less likely to be hospitalized for more than 3 days. CONCLUSION The length of stay after MIRP decreased between 2005 and 2008. Surgical expertise represented one of the main determinants of shorter length of stay.
Collapse
Affiliation(s)
- L Budäus
- Martiniclinic, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abdollah F, Sun M, Shariat SF, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 national comprehensive cancer network practice guidelines for bladder cancer treatment. Int Braz J Urol 2011. [DOI: 10.1590/s1677-55382011000300029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- F Abdollah
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - M Sun
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - SF Shariat
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - J Schmitges
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - O Djahangirian
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - Z Tian
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - C Jeldres
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - P Perrotte
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - F Montorsi
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | | |
Collapse
|
9
|
Jeldres C, Lughezzani G, Budäus L, Liberman D, Sun M, Shariat S, Perrotte P, Graefen M, Montorsi F, Karakiewicz P. 288 ASSESSMENT OF MORTALITY FOR NON CANCER-RELATED MORTALITY IN PATIENTS WITH HISTOLOGICALLY PROVEN SMALL RENAL MASSES MANAGED NON-SURGICALLY. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/s1569-9056(10)60287-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Abstract
Purpose Sorafenib represents one of the two standards of care for patients with metastatic renal cell carcinoma (mrcc). In the present review, we provide information regarding the use of sorafenib in first and second lines. We also describe results for dose escalation strategies. Finally, we provide data addressing the efficacy of sorafenib in patients with mrcc of non-clear-cell histology. Recent Findings Sorafenib is a valid first-line agent. Sorafenib response rates and toxicity are not affected by patient age or site of metastasis. The sequence of first-line sorafenib followed by second-line sunitinib resulted in a longer duration of response than did the opposite sequence. Sorafenib efficacy in first-line therapy can be potentiated by co-administration of low-dose interferon. Moreover, in first-line therapy, impressive response rates were recorded when the dose of sorafenib was escalated beyond the standard 400 mg twice daily. Similarly impressive response rates were observed with dose escalation in second-line therapy. It is notable that dose escalation after failure of standard sorafenib dose also prolongs progression-free survival. Finally, the efficacy of sorafenib is not limited to clear-cell histology, but also applies to chromophobe and papillary mrcc variants. Summary Sorafenib is a highly effective and well-tolerated agent for first- and second-line patients with clear-cell, chromophobe, or papillary mrcc variants.
Collapse
Affiliation(s)
- C. Guevremont
- Correspondence to: Catherine Guevremont, Campus St-Luc, 1058rue St-Denis, Montreal, QCH2X3J4. E-mail:
| | | | | | | |
Collapse
|
11
|
Isbarn H, Jeldres C, Capitanio U, Gallina A, Suardi N, Baillargeon-Gagne S, Shariat S, Duclos A, Lattouf J, Jolivet-Tremblay M, Perrotte P, Montorsi F, Graefen M, Karakiewicz P. 841 A SYSTEMATIC ANALYSIS OF THE DETRIMENTAL EFFECT OF ORCHIECTOMY ON 12 SYSTEMIC MORBIDITIES. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s1569-9056(09)60829-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Jeldres C, Gallina A, Walz J, Fred S, Perrotte P, Valiquette L, McCormack M, Huland H, Montorsi F, Karakiewicz P. The effect of surgical volume on the rate of secondary therapy after radical prostatectomy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15620 Introduction and Objective: Some argue that prostate cancer (PCa) detection and treatment at a younger age may translate into higher rate of clinically insignificant PCa. We assessed the effect of patients age at diagnosis on the pathological stage at radical prostatectomy (RP). Methods: Clinical and pathological data were available for 11975 patients from 3 European and 3 North American tertiary care centers. All RPs were performed between 1987 and 2006. Univariable and multivariable logistic regression analyses addressed the effect of age at RP on the rate of extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI), after controlling for PSA, clinical stage, biopsy Gleason sum and year of surgery. Age at RP was coded as cubic spline to allow non-linear effects. Results: Mean age was 61.6 years (range 32–85) and mean PSA was 8.7 ng/mL (range 0.1–50.0). Biopsy Gleason sum was 2–6, 7 or 8–10 in 7510 (62.7%), 3656 (30.5%) and 809 (6.8%) patients, respectively. At RP, ECE, SVI and LNI were identified in 3383 (28.3%), 1309 (10.9%) and 469 (3.9%), respectively. In multivariable analyses, age was only an independent predictor of SVI (p<0.001). Older men had a higher rate of SVI. Conclusions: Pathological age only affects the rate of SVI. However, only one in ten men harbored SVI and this percentage may decrease even further with ongoing stage migration. Nonetheless, these data suggest that the removal of seminal vesicles should not be omitted in older men. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Jeldres
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - A. Gallina
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - J. Walz
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - S. Fred
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - P. Perrotte
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - L. Valiquette
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - M. McCormack
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - H. Huland
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - F. Montorsi
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| | - P. Karakiewicz
- University of Montreal, Montreal, PQ, Canada; University of Hamburg, Hamburg, Germany; University Vita Salute, Milan, Italy
| |
Collapse
|
13
|
Porter C, Walz J, Gallina A, Jeldres C, Kodama K, Gibbons R, Correa R, Perrotte P, Benard F, Saad F, Karakiewicz P. 634 NATURAL HISTORY OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. EUR UROL SUPPL 2007. [DOI: 10.1016/s1569-9056(07)60632-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|